Background: In spite of the large number of studies that have evaluated DNA-based immunization, few have directly compared the iimmune responses generated by different routes of immunization, particularly in nonhuman primates. Here we examine the ability of a hepatitis B surface antigen (HBsAg)-encoding plasmid to induce immune responses in mice and non-human primates (rhesus monkeys: Macaca mulatta) after delivery by
jected and none of the six noninjected routes. The highest levels of anti-HBs were induced by IM and IV injections, although significant titers were also obtained with SL and ID. Each of these routes also induced CTL, as did IPER and VW and one noninjected route (INH) that failed to induce antibodies.
In a second study, GG (3) (4) (5) (6) . Unfortunately, the promising results in animal models have not been realized in human trials and considerable effort is now being focused at understanding this difference and developing ways of improving the efficacy of DNA vaccines.
The induction of strong immune responses in animal models following introduction of DNA appears to be due to a combination of (i) the prolonged in vivo synthesis of antigen (7), (ii) in vivo antigen expression that results in major histocompatability complex (MHC) presentation (8, 9) , and (iii) the adjuvant effect of unmethylated immunostimulatory CpG motifs present in G. Widera's current address is Gentronics Inc., San Diego, CA. J. R. Haynes Davis, Loeb Health Research Institute, 725 Parkdale Avenue, Ottawa, K1Y 4E9, Canada. Phone: 613-798-5555, x7682; Fax: 613-761-5354; E-mail: hdavis@lri.ca the DNA backbone (10,1 1). Thus, efforts to improve the efficacy of DNA vaccines include vector modifications, facilitated or targeted DNA delivery, and the use of adjuvants in an attempt to increase the amount of antigen expressed, to have the antigen expressed in the most appropriate cells and/or to improve the immune responses against the expressed antigen.
The strength and nature of immune responses in mice with DNA vaccines appear to be influenced by a number of factors (1,2); however, these variables may not be of similar importance in larger animals including humans. As such, optimization methods developed in mice may not necessarily be applicable to humans. Factors that have significant impact on subsequent immune responses in mice include the route and method of DNA delivery (12) (13) (14) , likely because of differences in the efficiency of gene transfer and the type of cell(s) transfected. DNA vaccines have been delivered to a wide variety of tissues by both injected and noninjected DNA delivery methods, including (i) into the muscle by gene gun (GG) or intramuscular (IM) injection (13, (15) (16) (17) (18) (19) (20) ; (ii) into the skin by epidermal GG delivery (9, 12, 21) or intradermal (ID) (12, 22, 23) or subcutaneous (SC) (12, 24) injection; (iii) into the circulatory system by intravenous (IV) injection (12, 25, 26) ; (iv) into the respiratory system by intranasal (IN) (12, (27) (28) (29) or intratracheal (12) delivery; (v) into the digestive system by oral feeding of microencapsulated (30,3 1) or lipid-formulated DNA (32) , injection into the oral mucosa (32) , tongue (33) , or jejunum (32) , and GG delivery into the Peyer's patches of the bowel (34) , tongue (35) , or oral mucosa (36) ; (vi) into the genitourinary tract by intravaginal (IVAG) GG delivery (34) or instillation (37, 38) , and (vii) by topical ocular (Oc) administration (39) .
In Al DNA slowly instilled into the mouse vaginal cavity using a 200-,l pipette tip, following which a small quantity of petroleum jelly was applied to prevent leakage (mice were anesthetized with Somnotol to prevent them from licking themselves and ingesting some of the DNA); Oc: 10 ,lI applied to each eyeball, following which the eyelids were gently massaged; oral feeding (oral): 100 ,lI administered directly into the stomach using a 1 -c.c. tuberculin syringe (Becton Dickinson) attached to a 20-gauge olive tip steel feeding tube (Fine Science Tools, North Vancouver, British Columbia), which was passed through the oral cavity and into the esophagus.
DNA-based Immunization of Monkeys
In one experiment (carried out at Bioqual), monkeys were immunized at 0, 4, and 8 weeks with pCMV-S2.S DNA by IM or ID injection (1 mg) or GG delivery to the skin (0.4 ,ug). In a separate experiment (carried out at Primedica), monkeys were treated similarly except pCMV-S DNA was given at 0, 12, and 24 weeks and the GG dose was increased to 3.2 jig. IM injections were performed with the Biojector® needle-free jet injection system (Bioject, Portland, OR) using a barrel size previously shown to deliver almost all radioopaque injectate into the muscle belly (data not shown) and ID injections using an insulin syringe with a 29-gauge needle attached (Becton Dickinson). We have previously shown that the Biojector is superior to IM injection for DNAbased immunization of rabbits (42) and Aotus monkeys (23 Evaluation of HBsAg-specific Immune Responses in Mice ANTI-HBs. Plasma was obtained by retro-orbital puncture at various time points after immunization. HBsAg-specific antibodies (anti-HBs) in plasma were detected by ELISA assay on individual samples using HBsAg-coated plates as previously described (43) . End-point dilution titers for total immunoglobulin G (IgG) as well as IgGI and IgG2a isotypes were defined as the highest plasma dilution that resulted in an absorbance value (OD 450) two times greater than that of nonimmune plasma, with a cut-off value of 0.05. In our laboratory we have previously determined that the relationship between end-point titers in mice and those in milli-international units (mIU), as defined by the World Health Organization (WHO), is close to 1:1 (44) . A value of 10 mIU/ml is protective in humans. In addition, a panel of mouse standards was identified by comparing various mouse sera against human-derived standards defined by the WHO (Monolisa Anti-HBs Standards, Sanofi Diagnostics Pasteur, Montreal, Quebec) using a commercial kit (Monolisa Anti-HBs, Sanofi Diagnostics Pasteur). These mouse standards were then used to quantify anti-HB titers in some mouse groups in mIU/ ml. Anti-HB titers were expressed as means (mIU/ml) or geometric means (end-point dilution) ± (Fig. 4A) . There was no significant effect on CTL activity in IM or ID groups by boosting mice in an identical manner at 2 weeks (not shown). CTL activity was weaker after two doses by GG administration than one dose by IM or ID injection (p < 0.002) (Fig. 4B) . It (Fig. 4) . Al- though no monkeys in this experiment had seroconverted by the time of the first boost, by 2 weeks post-boost, low levels of anti-HBs (10-100 mIU/ ml, p = 0.69) were detected in plasma of some monkeys immunized by IM (2/4) or IID (3/4), but not by GG (0/4). However, by 4 weeks after the first boost, one of the monkeys immunized by GG had seroconverted (16 mIU/ml). By 2 weeks after the second boost the number of responders increased for the IM and ID groups (3/4 and 4/4, respectively) and by 4 weeks post-boost for the GG group (2/4), with all animals attaining low to moderate levels (<1000 mIU/ml) and no significant differences among groups (p = 0.3) (Fig. 3B ).
EXPERIMENT 2 (BOOSTING AT 12 AND 24 WEEKS). At the time of the first boost, only a few monkeys had seroconverted (IM 1/4, ID 1/4, GG 2/4). By 2 weeks after a 12-week boost, most monkeys had seroconverted (IM 4/4, ID 2/4, GG 3/4) and anti-HB titers had peaked at 62 ± 54, 816 ± 461, and 1827 ± 742 mIU/ml for the ID, IM, and GG groups, respectively. However, over the following 6 weeks, anti-HB levels decreased 2-to 6-fold in all groups. A second boost given at 24 weeks raised anti-HB levels -20-fold by 2 When a large number of injected and noninjected routes were used to administer the DNA vaccine, anti-HBs were detected only in serum of mice treated by five of eight of the injected routes and by GG but none of the six noninjected routes. The highest levels of anti-HBs were induced by IM and IV injections, although reasonable titers were also obtained with sublingual and ID injections and GG delivery of DNA-coated gold particles to the epidermis. Each of these routes also induced CTL activity, but notably, CTL were also found with two other injected routes (perineum and vaginal wall injection) as well as one noninjected route (IN inhalation) that failed to induce antibodies. At one time it was thought that muscle was a preferred route for DNA vaccine delivery because early studies showed it to be more efficient than other tissues for the uptake and expression of plasmid DNA encoding reporter genes (58) and its postmitotic nature allowed expression from the episomally located plasmids to continue for many months (59) . However, more recent studies with antigen-encoding plasmids have shown that antigen expression does not continue indefinitely, but rather is lost by some immune-mediated mechanism around 2-3 weeks after DNA injection (7). Furthermore, even though immune responses are possible following transplantation of antigenexpressing myoblasts (60) , only professional antigen-presenting cells (APC) are actually capable of priming immune responses (60) (61) (62) (63) . Nevertheless, on the basis of findings that immune responses were unaffected when the injected muscle was removed within seconds of injection (64) , it is uncertain what role the relatively few antigen-expressing muscle fibers play after direct injection of DNA vaccines into muscle. Indeed, it is possible that direct transfection of APC may be necessary in the case of DNA vaccines, and following IM injection, such transfected APC are found in regional lymph nodes (65 29, 32) , the use of mucosal adjuvants (27, 28, 32) , microencapsulation for oral delivery (30, 31, 66) , or physical penetration of naked DNA into mucosal tissue using a GG (34, 36) .
A number of factors appear to influence the Th bias of the response, including (i) the antigen (20) ; (ii) the dose of antigen (67); (iii) whether the antigen is secreted, cytoplasmic, or membrane bound (68, 69) ; (iv) the route and method of DNA administration (13, 14, 63) ; (v) the number of immunizations (14, 70, 71) ; (vi) the presence of CpG motifs (10, 72) ; (vii) the haplotype of the mouse immunized (73); (viii) the presence of adjuvant (27, 28, 32) ; (ix) co-expression of cytokines (74, 75) ; (x) whether DNA is formulated (e.g., with cationic liposomes) (24,29,32); and (xi) rest period between immunizations (51,52). Previous studies have reported Th2-like or mixed ThI /Th2 responses with DNA delivery to the skin and more Thl-like responses with IM injection (13, 14, 19, 76, 77) , and this has been corroborated in the present study. However, antibody isotype did not change as a result of booster immunizations in the present study, which is in contrast with findings of other studies (14, 70) . These differences may be due to the nature of the encoded antigen, which can affect the antibody isotypes induced (20 (44) . Thus precise evaluation of the Th response may also require analysis of cytokine secretion from antigen-stimulated Th cells in vitro.
The realization that results in mice often do not predict the situation in humans has also led to a large number of DNA vaccine studies in non-human primates, including Aotus monkeys (23), rhesus monkeys (51, (78) (79) (80) , and chimpanzees (17, 38, (81) (82) (83) (84) . IM injection of plasmid DNA vaccines, while highly immunogenic in mice (see refs. 1,2) was found to be only relatively so in chimpanzees (17, 38, 79, 83) , and essentially not all in Aotus monkeys (23). Furthermore, although early human studies have demonstrated the safety and potential of DNA vaccines, results obtained have not been as good as predicted from animal models (3) (4) (5) (6) . Collectively, these results indicate that no animal model may be ideal for prediction of efficacy in humans. The relatively greater efficacy of IM in mice than primates may be related to morphological differences. Alternatively, it may be more related to dosage. The 10-to 100-,ug doses of DNA vaccine typically used in a 20-g mouse would be equivalent to 35 to 350 mg in a 70-kg human, a dose range greatly in excess of what has been used to date in human clinical trials.
In summary, mice may have limited value for choosing the best route of DNA vaccine delivery for humans. While efficacy in murine models has preceeded the successful development of many human vaccines, it is probably safe to say that any vaccine that works in a human will work in a mouse, but not necessarily vice versa. Therefore, it is difficult to predict from mouse studies the potential of a new vaccine for humans. In fact, in those human trials that have been carried out, none of the DNA vaccines induced the strong immune responses that had been seen in mice with the same vectors. Furthermore, although non-human primate models are frequently used for development and testing of human vaccines, it is not clear how predictive they will be in the case of DNA vaccines where efficacy, by virtue of the requirement first to transfect cells and express the antigen, relies on many factors other than immunological responses to the antigen. We will not know the answer to this until after greater experience has been achieved in non-human primates and human clinical trials. 
